NCT04039217View on ClinicalTrials.gov

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

August 28, 2020

Study Completion Date

August 28, 2020

Conditions
ARTHIV
Interventions
DRUG

Biktarvy

Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.

Trial Locations (1)

30322

Hope Clinic, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM | Biotech Hunter | Biotech Hunter